Stockscreener 앱 받기
1.19
0.85%
0.01
시간 외 거래:
1.76
0.57
+47.90%
전일 마감가:
$1.18
열려 있는:
$1.19
하루 거래량:
16,081
Relative Volume:
0.24
시가총액:
$13.02M
수익:
$3,000
순이익/손실:
$-8.23M
주가수익비율:
-0.8436
EPS:
-1.4107
순현금흐름:
$-7.44M
1주 성능:
-1.65%
1개월 성능:
-5.56%
6개월 성능:
-23.72%
1년 성능:
-41.95%
1일 변동 폭
$1.1572
$1.20
1주일 범위
$1.08
$1.25
52주 변동 폭
$1.00
$3.20
Biocardia Inc Stock (BCDA) Company Profile
명칭
Biocardia Inc
전화
650-226-0123
주소
320 SOQUEL WAY, SUNNYVALE, CA
Compare BCDA vs MOBBW, GOODO, PSNYW, SHMD, DWLD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| 0.41 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
1.82 | 2.55B | 0 | 0 | 0 | 0.00 |
GOODO
Gladstone Commercial Corporation
|
19.85 | 372.90M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
3.70 | 356.14M | 2.07B | -1.42B | -1.37B | -0.6765 |
SHMD
Schmid Group N V
|
5.81 | 315.27M | 52.15M | -21.46M | 0 | -0.4675 |
DWLD
Davis Select Worldwide ETF
|
46.21 | 0 | 0 | 0 | 0 | 0.00 |
Biocardia Inc Stock (BCDA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-04-16 | 다운그레이드 | Dawson James | Buy → Neutral |
Biocardia Inc 주식(BCDA)의 최신 뉴스
Investment Report: Can BioCardia Inc expand its profit marginsDay Trade & Safe Capital Growth Plans - baoquankhu1.vn
BioCardia (BCDA) price target decreased by 38.00% to 15.81 - MSN
Guidance Update: Can BioCardia Inc ride the EV waveMarket Risk Report & Daily Volume Surge Signals - baoquankhu1.vn
BCDA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Surprises Report: Is BioCardia Inc in a long term uptrendTrade Performance Summary & Smart Money Movement Tracker - baoquankhu1.vn
BioCardia, Inc. (NASDAQ:BCDA) Q4 2025 earnings call transcript - MSN
BioCardia, Inc. (BCDA) stock price, news, quote and history - Yahoo Finance UK
BioCardia submits heart failure trial data to FDA By Investing.com - Investing.com Canada
BioCardia Requests FDA Meeting On Accelerated Approval For CardiAMP In Heart Failure - TradingView
BioCardia Requests FDA Meeting to Discuss Accelerated Approval for CardiAMP Cell Therapy System - geneonline.com
BioCardia submits heart failure trial data to FDA - Investing.com
BioCardia Files Request for Meeting With FDA to Discuss Accelerated Approval Pathway for CardiAMP® System in Ischemic Heart Failure - The Manila Times
BioCardia Submits CardiAMP HF Study Data to FDA, Plans Meeting for Accelerated Approval Discussion - Quiver Quantitative
Heart failure subgroup saw 47% lower cardiac death as BioCardia heads to FDA - Stock Titan
BioCardia Seeks Accelerated FDA Pathway for CardiAMP HF - TipRanks
BioCardia files FDA meeting request on accelerated approval for CardiAMP after CardiAMP HF data submission - TradingView
BioCardia (NASDAQ: BCDA) pursues FDA accelerated path for CardiAMP HF - Stock Titan
Revenue per share of BioCardia, Inc. – FWB:6JU0 - TradingView
Book value per share of BioCardia, Inc. – FWB:6JU0 - TradingView
Portfolio Shifts: Can BioCardia Inc expand its profit marginsQuarterly Earnings Summary & Technical Confirmation Trade Alerts - baoquankhu1.vn
Altman Peter, president of BioCardia, buys BCDA stock worth $1.1k - Investing.com UK
Insider Buying: Peter Altman Acquires Additional Shares of BioCa - GuruFocus
Altman Peter, president of BioCardia, buys BCDA stock worth $1.1k By Investing.com - za.investing.com
BioCardia (BCDA) CEO adds 900 shares in open‑market stock purchases - Stock Titan
Layoff Watch: Is BioCardia Inc in a long term uptrend2026 Trends & Weekly Consistent Profit Watchlists - baoquankhu1.vn
BioCardia, Inc. (NASDAQ:BCDA) Q4 2025 Earnings Call Transcript - insidermonkey.com
BioCardia, Inc. Q4 2025 Earnings Call Summary - finance.yahoo.com
BioCardia, Inc. Reports 2026 Financial Results and CardiAMP Clinical Program Updates - Minichart
BioCardia (BCDA) Projected to Post Quarterly Earnings on Wednesday - Defense World
BioCardia outlines imminent CardiAMP FDA submission and targets regulatory catalysts as trial data signals clinical benefit - MSN
BioCardia Inc (BCDA) Q4 2025 Earnings Call Highlights: Promising Clinical Results Amid ... By GuruFocus - Investing.com Canada
BioCardia Inc (BCDA) Q4 2025 Earnings Call Highlights: Promising Clinical Results Amid Financial Challenges - GuruFocus
BioCardia (BCDA) Highlights Clinical Progress and Financials in Q4 2025 - GuruFocus
BioCardia, Inc.: Advancing Cell Therapy Systems for Heart Failure and Cardiovascular Disease – Clinical Trials, FDA Approvals, and Business Strategies (2025) - Minichart
Earnings Call Summary | BioCardia(BCDA.US) Q4 2025 Earnings Conference - 富途牛牛
BioCardia, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:BCDA) 2026-03-24 - Seeking Alpha
Biocardia Inc's HF2 Trial Enrollment and Regulatory Timeline Claims Clash in 2025 Earnings Calls - Bitget
Earnings call transcript: Biocardia’s Q4 2025 results show focus on clinical progress By Investing.com - Investing.com South Africa
BCDA: Phase III CardiAMP HF data support regulatory filings as financials remain stable and catalysts approach - TradingView
Earnings call transcript: Biocardia’s Q4 2025 results show focus on clinical progress - Investing.com Canada
BioCardia Inc reports results for the quarter ended December 31Earnings Summary - tradingview.com
BCDA: CardiAMP therapy advances toward regulatory approval with strong clinical data and stable finances - TradingView
BIOCARDIA ($BCDA) Releases Q4 2025 Earnings - Quiver Quantitative
BCDA: Positive clinical trial results and regulatory progress, but net loss widened to $8.2 million - TradingView
Q4 2025 BioCardia Inc Earnings Call Transcript - gurufocus.com
[10-K] BioCardia, Inc. Files Annua... - Stock Titan
BioCardia Reports 2025 Business Highlights and Financial Results - The Manila Times
BioCardia, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
BioCardia Inc expected to post a loss of 17 cents a shareEarnings Preview - TradingView
BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026 - The Manila Times
BioCardia, Inc. to Host Conference Call for 2025 Financial Results and Corporate Update on March 24, 2026 - Quiver Quantitative
Biocardia Inc (BCDA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):